Hakutulokset - Laura M. Spring

Tarkenna hakua
  1. 1
    The Evolving Role of Neoadjuvant Therapy for Operable Breast Cancer

    The Evolving Role of Neoadjuvant Therapy for Operable Breast Cancer Tekijä Laura M. Spring, Yael Bar, Steven J. Isakoff

    Julkaistu 2022
    Hae kokoteksti Hae kokoteksti
    Revisão
    Lisää suosikkeihin
    Tallennettuna:
  2. 2
    Clinical Management of Potential Toxicities and Drug Interactions Related to Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Practical Considerations and Recommendations

    Clinical Management of Potential Toxicities and Drug Interactions Related to Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Practical Considerations and Recommendations Tekijä Laura M. Spring, Mark L. Zangardi, Beverly Moy, Aditya Bardia

    Julkaistu 2017
    Hae kokoteksti Hae kokoteksti
    Revisão
    Lisää suosikkeihin
    Tallennettuna:
  3. 3
    Impact of pass/fail grading on medical students’ well-being and academic outcomes

    Impact of pass/fail grading on medical students’ well-being and academic outcomes Tekijä Laura M. Spring, Diana Robillard, Lorrie Gehlbach, Tiffany A. Moore Simas

    Julkaistu 2011
    Hae kokoteksti Hae kokoteksti
    Revisão
    Lisää suosikkeihin
    Tallennettuna:
  4. 4
    CDK 4/6 Inhibitors in Breast Cancer: Current Controversies and Future Directions

    CDK 4/6 Inhibitors in Breast Cancer: Current Controversies and Future Directions Tekijä Laura M. Spring, Seth A. Wander, Mark L. Zangardi, Aditya Bardia

    Julkaistu 2019
    Hae kokoteksti
    Revisão
    Lisää suosikkeihin
    Tallennettuna:
  5. 5
    ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer

    ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer Tekijä Jamie O. Brett, Laura M. Spring, Aditya Bardia, Seth A. Wander

    Julkaistu 2021
    Hae kokoteksti Hae kokoteksti
    Revisão
    Lisää suosikkeihin
    Tallennettuna:
  6. 6
    Mechanisms of Resistance to CDK4/6 Blockade in Advanced Hormone Receptor–positive, HER2-negative Breast Cancer and Emerging Therapeutic Opportunities

    Mechanisms of Resistance to CDK4/6 Blockade in Advanced Hormone Receptor–positive, HER2-negative Breast Cancer and Emerging Therapeutic Opportunities Tekijä Maxwell R. Lloyd, Laura M. Spring, Aditya Bardia, Seth A. Wander

    Julkaistu 2021
    Hae kokoteksti Hae kokoteksti
    Revisão
    Lisää suosikkeihin
    Tallennettuna:
  7. 7
    Mechanisms of Resistance to Antibody–Drug Conjugates

    Mechanisms of Resistance to Antibody–Drug Conjugates Tekijä Rachel O. Abelman, Bogang Wu, Laura M. Spring, Leif W. Ellisen, Aditya Bardia

    Julkaistu 2023
    Hae kokoteksti Hae kokoteksti
    Revisão
    Lisää suosikkeihin
    Tallennettuna:
  8. 8
    Neoadjuvant Endocrine Therapy for Estrogen Receptor–Positive Breast Cancer

    Neoadjuvant Endocrine Therapy for Estrogen Receptor–Positive Breast Cancer Tekijä Laura M. Spring, Arjun Gupta, Kerry L. Reynolds, Michele A. Gadd, Leif W. Ellisen, Steven J. Isakoff, Beverly Moy, Aditya Bardia

    Julkaistu 2016
    Hae kokoteksti
    Revisão
    Lisää suosikkeihin
    Tallennettuna:
  9. 9
    Sacituzumab Govitecan for Metastatic Triple-Negative Breast Cancer: Clinical Overview and Management of Potential Toxicities

    Sacituzumab Govitecan for Metastatic Triple-Negative Breast Cancer: Clinical Overview and Management of Potential Toxicities Tekijä Laura M. Spring, Erika Nakajima, Jennifer Hutchinson, Elene Viscosi, Gayle C. Blouin, Colin D. Weekes, Hope S. Rugo, Beverly Moy, Aditya Bardia

    Julkaistu 2021
    Hae kokoteksti Hae kokoteksti
    Revisão
    Lisää suosikkeihin
    Tallennettuna:
  10. 10
    Polyclonal RB1 mutations and acquired resistance to CDK 4/6 inhibitors in patients with metastatic breast cancer

    Polyclonal RB1 mutations and acquired resistance to CDK 4/6 inhibitors in patients with metastatic breast cancer Tekijä Rosaria Condorelli, Laura M. Spring, Joyce O’Shaughnessy, Ludovic Lacroix, Caroline Bailleux, Véronique Scott, Jon S. Dubois, Rebecca J. Nagy, Richard B. Lanman, A. John Iafrate, Fabrice André, Aditya Bardia

    Julkaistu 2017
    Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  11. 11
    Dynamic HER2-low status among patients with triple negative breast cancer (TNBC) and the impact of repeat biopsies

    Dynamic HER2-low status among patients with triple negative breast cancer (TNBC) and the impact of repeat biopsies Tekijä Yael Bar, Geoffrey Fell, Aylin S. Dedeoglu, Natalie Moffett, Neelima Vidula, Laura M. Spring, Seth A. Wander, Aditya Bardia, Naomi Y. Ko, Beverly Moy, Leif W. Ellisen, Steven J. Isakoff

    Julkaistu 2025
    Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  12. 12
    Pathologic Complete Response after Neoadjuvant Chemotherapy and Impact on Breast Cancer Recurrence and Survival: A Comprehensive Meta-analysis

    Pathologic Complete Response after Neoadjuvant Chemotherapy and Impact on Breast Cancer Recurrence and Survival: A Comprehensive Meta-analysis Tekijä Laura M. Spring, Geoffrey Fell, Andrea Arfè, Chandni Sharma, Rachel A. Greenup, Kerry L. Reynolds, Barbara L. Smith, Brian M. Alexander, Beverly Moy, Steven J. Isakoff, Giovanni Parmigiani, Lorenzo Trippa, Aditya Bardia

    Julkaistu 2020
    Hae kokoteksti
    Carta
    Lisää suosikkeihin
    Tallennettuna:
  13. 13
    Pathologic Complete Response After Neoadjuvant Chemotherapy and Long-Term Outcomes Among Young Women With Breast Cancer

    Pathologic Complete Response After Neoadjuvant Chemotherapy and Long-Term Outcomes Among Young Women With Breast Cancer Tekijä Laura M. Spring, Rachel A. Greenup, Andrzej Niemierko, Lidia Schapira, Stephanie Haddad, Rachel Jimenez, Suzanne B. Coopey, Alphonse G. Taghian, Kevin S. Hughes, Steven J. Isakoff, Leif W. Ellisen, Barbara L. Smith, Michelle C. Specht, Beverly Moy, Aditya Bardia

    Julkaistu 2017
    Hae kokoteksti Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  14. 14
    Neoadjuvant HER2-targeted therapy with or without immunotherapy with pembrolizumab (neoHIP): An open label randomized phase II trial

    Neoadjuvant HER2-targeted therapy with or without immunotherapy with pembrolizumab (neoHIP): An open label randomized phase II trial Tekijä Heather L. McArthur, J.H.S. Leal, David B. Page, Aditya Bardia, Laura M. Spring, Christina DiLauro Abaya, Reva Basho, Lindsey Ristow, Hannah Coleman, Stephen L. Shiao, Simon Knott, Mourad Tighiouart, Farnaz Dadmanesh, Sunil Verma, A. E. Giuliano

    Julkaistu 2019
    Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  15. 15
    A Digital RNA Signature of Circulating Tumor Cells Predicting Early Therapeutic Response in Localized and Metastatic Breast Cancer

    A Digital RNA Signature of Circulating Tumor Cells Predicting Early Therapeutic Response in Localized and Metastatic Breast Cancer Tekijä Tanya T. Kwan, Aditya Bardia, Laura M. Spring, Anita Giobbie‐Hurder, Mark Kalinich, Taronish D. Dubash, Tilak Sundaresan, Xin Hong, Joseph A. LiCausi, Uyen Ho, Erin J. Silva, Ben S. Wittner, Lecia V. Sequist, Ravi Kapur, David T. Miyamoto, Mehmet Toner, Daniel A. Haber, Shyamala Maheswaran

    Julkaistu 2018
    Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  16. 16
    <i>FGFR1</i> Amplification Mediates Endocrine Resistance but Retains TORC Sensitivity in Metastatic Hormone Receptor–Positive (HR+) Breast Cancer

    <i>FGFR1</i> Amplification Mediates Endocrine Resistance but Retains TORC Sensitivity in Metastatic Hormone Receptor–Positive (HR+) Breast Cancer Tekijä Joshua Z. Drago, Luigi Formisano, Dejan Juric, Andrzej Niemierko, Alberto Servetto, Seth A. Wander, Laura M. Spring, Neelima Vidula, Jerry Younger, Jeffrey Peppercorn, Megan Yuen, Giuliana Malvarosa, Dennis C. Sgroi, Steven J. Isakoff, Beverly Moy, Leif W. Ellisen, A. John Iafrate, Carlos L. Arteaga, Aditya Bardia

    Julkaistu 2019
    Hae kokoteksti Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  17. 17
    Serial single-cell genomics reveals convergent subclonal evolution of resistance as patients with early-stage breast cancer progress on endocrine plus CDK4/6 therapy

    Serial single-cell genomics reveals convergent subclonal evolution of resistance as patients with early-stage breast cancer progress on endocrine plus CDK4/6 therapy Tekijä Jason I. Griffiths, Jinfeng Chen, Patrick A. Cosgrove, Anne O’Dea, Priyanka Sharma, X. Cynthia, Meghna S. Trivedi, Kevin Kalinsky, Kari B. Wisinski, Ruth O’Regan, Issam Makhoul, Laura M. Spring, Aditya Bardia, Frederick R. Adler, Adam L. Cohen, Jeffrey T. Chang, Qamar J. Khan, Andrea H. Bild

    Julkaistu 2021
    Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  18. 18
    Managing hyperglycemia and rash associated with alpelisib: expert consensus recommendations using the Delphi technique

    Managing hyperglycemia and rash associated with alpelisib: expert consensus recommendations using the Delphi technique Tekijä Emily J. Gallagher, Heather Moore, Mario E. Lacouture, Susan Dent, Azeez Farooki, Marcus D. Goncalves, Claudine Isaacs, Abigail Johnston, Dejan Juric, Zoe Quandt, Laura M. Spring, Brian Berman, Melanie Decker, Gabriel N. Hortobágyi, Benjamin H. Kaffenberger, Bernice Y. Kwong, Timothy Pluard, Ruta Rao, Lee S. Schwartzberg, Michael S. Broder

    Julkaistu 2024
    Hae kokoteksti Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  19. 19
    Chemotherapy elicits pro-metastatic extracellular vesicles in breast cancer models

    Chemotherapy elicits pro-metastatic extracellular vesicles in breast cancer models Tekijä Ioanna Keklikoglou, Chiara Cianciaruso, Esra Güç, Mario Leonardo Squadrito, Laura M. Spring, Simon Tazzyman, Lore Lambein, Amanda Poissonnier, Gino B. Ferraro, Caroline Baer, Antonino Cassará, Alan Guichard, M. Luisa Iruela‐Arispe, Claire E. Lewis, Lisa M. Coussens, Aditya Bardia, Rakesh K. Jain, Jeffrey W. Pollard, Michele De Palma

    Julkaistu 2018
    Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  20. 20
    Impact of HER2 Heterogeneity on Treatment Response of Early-Stage HER2-Positive Breast Cancer: Phase II Neoadjuvant Clinical Trial of T-DM1 Combined with Pertuzumab

    Impact of HER2 Heterogeneity on Treatment Response of Early-Stage HER2-Positive Breast Cancer: Phase II Neoadjuvant Clinical Trial of T-DM1 Combined with Pertuzumab Tekijä Otto Metzger, Giuseppe Viale, Shayna Stein, Lorenzo Trippa, Denise A. Yardley, Ingrid A. Mayer, Vandana G. Abramson, Carlos L. Arteaga, Laura M. Spring, Adrienne G. Waks, Eileen Wrabel, Michelle K. DeMeo, Aditya Bardia, Patrizia DellʼOrto, Leila Russo, Tari A. King, Kornélia Polyák, Franziska Michor, Eric P. Winer, Ian E. Krop

    Julkaistu 2021
    Hae kokoteksti Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:

Työkalut: